STOCK TITAN

Catalent, Inc. Announces Second Quarter Fiscal Year 2024 Earnings Conference Webcast

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Catalent, Inc. (CTLT) will release financial results for the second quarter of fiscal year 2024 on February 9, 2024. The webcast to discuss the results will be accessible through Catalent’s website. The Company’s management will host the webcast at 8:15 a.m. ET on the same day.
Positive
  • None.
Negative
  • None.

SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release financial results for the second quarter of fiscal year 2024 ended December 31, 2023, before the market open on Friday, February 9, 2024. The Company’s management will host a webcast to discuss the results at 8:15 a.m. ET on the same day.

Catalent invites all interested parties to listen to the webcast and view a supplemental slide presentation, both of which will be accessible through Catalent’s website at https://investor.catalent.com. The webcast replay, along with the supplemental slides, will be available for 90 days at https://investor.catalent.com.

About Catalent

Catalent, Inc., is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,500 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply approximately 70 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of nearly 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $4.3 billion in revenue in its 2023 fiscal year.

Investor Contact:

Paul Surdez, Catalent, Inc.

(732) 537-6325

investors@catalent.com

Source: Catalent, Inc.

Catalent, Inc. (CTLT) will release financial results for the second quarter of fiscal year 2024 on February 9, 2024.

The webcast to discuss the results will be accessible through Catalent’s website.

The Company’s management will host the webcast at 8:15 a.m. ET on February 9, 2024.

The webcast replay, along with the supplemental slides, will be available for 90 days at https://investor.catalent.com.
Catalent Inc.

NYSE:CTLT

CTLT Rankings

CTLT Latest News

CTLT Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing

About CTLT

catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p